Infliksymab (Polish Wikipedia)

Analysis of information sources in references of the Wikipedia article "Infliksymab" in Polish language version.

refsWebsite

Global rank Polish rank

14nih.gov

4^th place

7^th place

13doi.org

2^nd place

6^th place

12worldcat.org

5^th place

2^nd place

2web.archive.org

1^st place

1pulsmedycyny.com.pl

low place

1wiley.com

222^nd place

228^th place

doi.org

dx.doi.org

S.P.L.S.P.L. Travis S.P.L.S.P.L. i inni, European evidence based consensus on the diagnosis and management of Crohn’s disease: current management, „Gut”, 55 (suppl 1), 2006, i16–i35, DOI: 10.1136/gut.2005.081950b, ISSN 0017-5749, PMID: 16481629, PMCID: PMC1859997 (ang.).
YokoY. Furuya YokoY. i inni, Theory based analysis of anti-inflammatory effect of infliximab on Crohn's disease, „Drug Metabolism and Pharmacokinetics”, 22 (1), 2007, s. 20–25, DOI: 10.2133/dmpk.22.20, ISSN 1347-4367, PMID: 17329907 .
E. William St.E.W.S. Clair E. William St.E.W.S. i inni, Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: A randomized, controlled trial, „Arthritis & Rheumatism”, 50 (11), 2004, s. 3432–3443, DOI: 10.1002/art.20568, ISSN 1529-0131, PMID: 15529377 (ang.).
RavinderR. Maini RavinderR. i inni, Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial, „The Lancet”, 354 (9194), 1999, s. 1932–1939, DOI: 10.1016/s0140-6736(99)05246-0, ISSN 0140-6736, PMID: 10622295 (ang.).
PaulP. Rutgeerts PaulP. i inni, Infliximab for induction and maintenance therapy for ulcerative colitis, „The New England Journal of Medicine”, 353 (23), 2005, s. 2462–2476, DOI: 10.1056/NEJMoa050516, ISSN 1533-4406, PMID: 16339095 .
J.J. Braun J.J. i inni, International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis, „Annals of the Rheumatic Diseases”, 62 (9), 2003, s. 817–824, DOI: 10.1136/ard.62.9.817, ISSN 0003-4967, PMID: 12922952, PMCID: PMC1754665 .
Alice BA.B. Gottlieb Alice BA.B., Infliximab for psoriasis, „Journal of the American Academy of Dermatology”, 49 (2, Suplement), 2003, s. 112–117, DOI: 10.1016/s0190-9622(03)01143-5, ISSN 0190-9622, PMID: 12894134 (ang.).
Alice B.A.B. Gottlieb Alice B.A.B. i inni, Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis, „Journal of the American Academy of Dermatology”, 48 (6), 2003, s. 829–835, DOI: 10.1067/mjd.2003.307, ISSN 0190-9622, PMID: 12789171 .
Alice B.A.B. Gottlieb Alice B.A.B. i inni, Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial, „Journal of the American Academy of Dermatology”, 51 (4), 2004, s. 534–542, DOI: 10.1016/j.jaad.2004.02.021, ISSN 1097-6787, PMID: 15389187 .
Shirish R.S.R. Sangle Shirish R.S.R., Graham R.V.G.R.V. Hughes Graham R.V.G.R.V., David P.D.P. D'Cruz David P.D.P., Infliximab in patients with systemic vasculitis that is difficult to treat: poor outcome and significant adverse effects, „Annals of the Rheumatic Diseases”, 66 (4), 2007, s. 564–565, DOI: 10.1136/ard.2006.065623, ISSN 0003-4967, PMID: 17360788, PMCID: PMC1856044 .
P.P.P.P. Sfikakis P.P.P.P., Behçet's disease: a new target for anti-tumour necrosis factor treatment, „Annals of the Rheumatic Diseases”, 61 Suppl 2, 2002, ii51–53, DOI: 10.1136/ard.61.suppl_2.ii51, ISSN 0003-4967, PMID: 12379622, PMCID: PMC1766720 .
Jean-FredericJ.F. Colombel Jean-FredericJ.F. i inni, The safety profile of infliximab in patients with Crohn’s disease: The Mayo Clinic experience in 500 patients, „Gastroenterology”, 126 (1), 2004, s. 19–31, DOI: 10.1053/j.gastro.2003.10.047, ISSN 0016-5085, PMID: 14699483 (ang.).

doi.org

HJ. Bovenschen, M. Tjioe, H. Vermaat, D. de Hoop i inni. Induction of eruptive benign melanocytic naevi by immune suppressive agents, including biologicals.. „Br J Dermatol”. 154 (5), s. 880-4, May 2006. DOI: 10.1111/j.1365-2133.2006.07189.x. PMID: 16634890.

nih.gov

ncbi.nlm.nih.gov

S.P.L.S.P.L. Travis S.P.L.S.P.L. i inni, European evidence based consensus on the diagnosis and management of Crohn’s disease: current management, „Gut”, 55 (suppl 1), 2006, i16–i35, DOI: 10.1136/gut.2005.081950b, ISSN 0017-5749, PMID: 16481629, PMCID: PMC1859997 (ang.).
YokoY. Furuya YokoY. i inni, Theory based analysis of anti-inflammatory effect of infliximab on Crohn's disease, „Drug Metabolism and Pharmacokinetics”, 22 (1), 2007, s. 20–25, DOI: 10.2133/dmpk.22.20, ISSN 1347-4367, PMID: 17329907 .
E. William St.E.W.S. Clair E. William St.E.W.S. i inni, Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: A randomized, controlled trial, „Arthritis & Rheumatism”, 50 (11), 2004, s. 3432–3443, DOI: 10.1002/art.20568, ISSN 1529-0131, PMID: 15529377 (ang.).
RavinderR. Maini RavinderR. i inni, Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial, „The Lancet”, 354 (9194), 1999, s. 1932–1939, DOI: 10.1016/s0140-6736(99)05246-0, ISSN 0140-6736, PMID: 10622295 (ang.).
PaulP. Rutgeerts PaulP. i inni, Infliximab for induction and maintenance therapy for ulcerative colitis, „The New England Journal of Medicine”, 353 (23), 2005, s. 2462–2476, DOI: 10.1056/NEJMoa050516, ISSN 1533-4406, PMID: 16339095 .
J.J. Braun J.J. i inni, International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis, „Annals of the Rheumatic Diseases”, 62 (9), 2003, s. 817–824, DOI: 10.1136/ard.62.9.817, ISSN 0003-4967, PMID: 12922952, PMCID: PMC1754665 .
DD. Gladman, PJ. Mease. Towards international guidelines for the management of psoriatic arthritis.. „J Rheumatol”. 33 (7), s. 1228-30, Jul 2006. PMID: 16821263.
Alice BA.B. Gottlieb Alice BA.B., Infliximab for psoriasis, „Journal of the American Academy of Dermatology”, 49 (2, Suplement), 2003, s. 112–117, DOI: 10.1016/s0190-9622(03)01143-5, ISSN 0190-9622, PMID: 12894134 (ang.).
Alice B.A.B. Gottlieb Alice B.A.B. i inni, Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis, „Journal of the American Academy of Dermatology”, 48 (6), 2003, s. 829–835, DOI: 10.1067/mjd.2003.307, ISSN 0190-9622, PMID: 12789171 .
Alice B.A.B. Gottlieb Alice B.A.B. i inni, Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial, „Journal of the American Academy of Dermatology”, 51 (4), 2004, s. 534–542, DOI: 10.1016/j.jaad.2004.02.021, ISSN 1097-6787, PMID: 15389187 .
Shirish R.S.R. Sangle Shirish R.S.R., Graham R.V.G.R.V. Hughes Graham R.V.G.R.V., David P.D.P. D'Cruz David P.D.P., Infliximab in patients with systemic vasculitis that is difficult to treat: poor outcome and significant adverse effects, „Annals of the Rheumatic Diseases”, 66 (4), 2007, s. 564–565, DOI: 10.1136/ard.2006.065623, ISSN 0003-4967, PMID: 17360788, PMCID: PMC1856044 .
P.P.P.P. Sfikakis P.P.P.P., Behçet's disease: a new target for anti-tumour necrosis factor treatment, „Annals of the Rheumatic Diseases”, 61 Suppl 2, 2002, ii51–53, DOI: 10.1136/ard.61.suppl_2.ii51, ISSN 0003-4967, PMID: 12379622, PMCID: PMC1766720 .
Jean-FredericJ.F. Colombel Jean-FredericJ.F. i inni, The safety profile of infliximab in patients with Crohn’s disease: The Mayo Clinic experience in 500 patients, „Gastroenterology”, 126 (1), 2004, s. 19–31, DOI: 10.1053/j.gastro.2003.10.047, ISSN 0016-5085, PMID: 14699483 (ang.).
HJ. Bovenschen, M. Tjioe, H. Vermaat, D. de Hoop i inni. Induction of eruptive benign melanocytic naevi by immune suppressive agents, including biologicals.. „Br J Dermatol”. 154 (5), s. 880-4, May 2006. DOI: 10.1111/j.1365-2133.2006.07189.x. PMID: 16634890.

pulsmedycyny.com.pl

Informacja na stronie Puls Medycyny. [dostęp 2009-02-22]. [zarchiwizowane z tego adresu (2008-06-15)].

web.archive.org

Informacja na stronie Puls Medycyny. [dostęp 2009-02-22]. [zarchiwizowane z tego adresu (2008-06-15)].
Information for the Arthritis Advisory Committee. REMICADE® (infliximab). Efficacy and Safety Review. 04 March 2003

wiley.com

www3.interscience.wiley.com

E. William St.E.W.S. Clair E. William St.E.W.S. i inni, Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: A randomized, controlled trial, „Arthritis & Rheumatism”, 50 (11), 2004, s. 3432–3443, DOI: 10.1002/art.20568, ISSN 1529-0131, PMID: 15529377 (ang.).

worldcat.org

S.P.L.S.P.L. Travis S.P.L.S.P.L. i inni, European evidence based consensus on the diagnosis and management of Crohn’s disease: current management, „Gut”, 55 (suppl 1), 2006, i16–i35, DOI: 10.1136/gut.2005.081950b, ISSN 0017-5749, PMID: 16481629, PMCID: PMC1859997 (ang.).
YokoY. Furuya YokoY. i inni, Theory based analysis of anti-inflammatory effect of infliximab on Crohn's disease, „Drug Metabolism and Pharmacokinetics”, 22 (1), 2007, s. 20–25, DOI: 10.2133/dmpk.22.20, ISSN 1347-4367, PMID: 17329907 .
E. William St.E.W.S. Clair E. William St.E.W.S. i inni, Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: A randomized, controlled trial, „Arthritis & Rheumatism”, 50 (11), 2004, s. 3432–3443, DOI: 10.1002/art.20568, ISSN 1529-0131, PMID: 15529377 (ang.).
RavinderR. Maini RavinderR. i inni, Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial, „The Lancet”, 354 (9194), 1999, s. 1932–1939, DOI: 10.1016/s0140-6736(99)05246-0, ISSN 0140-6736, PMID: 10622295 (ang.).
PaulP. Rutgeerts PaulP. i inni, Infliximab for induction and maintenance therapy for ulcerative colitis, „The New England Journal of Medicine”, 353 (23), 2005, s. 2462–2476, DOI: 10.1056/NEJMoa050516, ISSN 1533-4406, PMID: 16339095 .
J.J. Braun J.J. i inni, International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis, „Annals of the Rheumatic Diseases”, 62 (9), 2003, s. 817–824, DOI: 10.1136/ard.62.9.817, ISSN 0003-4967, PMID: 12922952, PMCID: PMC1754665 .
Alice BA.B. Gottlieb Alice BA.B., Infliximab for psoriasis, „Journal of the American Academy of Dermatology”, 49 (2, Suplement), 2003, s. 112–117, DOI: 10.1016/s0190-9622(03)01143-5, ISSN 0190-9622, PMID: 12894134 (ang.).
Alice B.A.B. Gottlieb Alice B.A.B. i inni, Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis, „Journal of the American Academy of Dermatology”, 48 (6), 2003, s. 829–835, DOI: 10.1067/mjd.2003.307, ISSN 0190-9622, PMID: 12789171 .
Alice B.A.B. Gottlieb Alice B.A.B. i inni, Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial, „Journal of the American Academy of Dermatology”, 51 (4), 2004, s. 534–542, DOI: 10.1016/j.jaad.2004.02.021, ISSN 1097-6787, PMID: 15389187 .
Shirish R.S.R. Sangle Shirish R.S.R., Graham R.V.G.R.V. Hughes Graham R.V.G.R.V., David P.D.P. D'Cruz David P.D.P., Infliximab in patients with systemic vasculitis that is difficult to treat: poor outcome and significant adverse effects, „Annals of the Rheumatic Diseases”, 66 (4), 2007, s. 564–565, DOI: 10.1136/ard.2006.065623, ISSN 0003-4967, PMID: 17360788, PMCID: PMC1856044 .
P.P.P.P. Sfikakis P.P.P.P., Behçet's disease: a new target for anti-tumour necrosis factor treatment, „Annals of the Rheumatic Diseases”, 61 Suppl 2, 2002, ii51–53, DOI: 10.1136/ard.61.suppl_2.ii51, ISSN 0003-4967, PMID: 12379622, PMCID: PMC1766720 .
Jean-FredericJ.F. Colombel Jean-FredericJ.F. i inni, The safety profile of infliximab in patients with Crohn’s disease: The Mayo Clinic experience in 500 patients, „Gastroenterology”, 126 (1), 2004, s. 19–31, DOI: 10.1053/j.gastro.2003.10.047, ISSN 0016-5085, PMID: 14699483 (ang.).